Download presentation
Presentation is loading. Please wait.
Published byPhilip Maxwell Modified over 9 years ago
1
r Slide # 1 VALGANCICLOVIR FOR THE TREATMENT OF CMV RETINITIS
2
r Slide # 2 GOAL Roche seeks approval recommendation: Valganciclovir (Val-GCV) is indicated for the treatment of CMV retinitis in patients with AIDS
3
r Slide # 3 AGENDA AND PRESENTERS DEVELOPMENT PROGRAM & STUDY RESULTS - Mary Jean Stempien, MD, MS INTRODUCTION - Mary Jean Stempien, MD, MS Director, Medical Research, Roche CLINICAL BACKGROUND - Daniel F. Martin, MD Associate Professor of Ophthalmology Emory University School of Medicine
4
r Slide # 4 EXPERTS Gary Koch, Ph.D. Professor of Biostatistics University of North Carolina, Chapel Hill Nancy C. Sambol, Pharm.D. Associate Clinical Professor Department of Biopharmaceutical Sciences University of California, San Francisco
5
r Slide # 5 CLINICAL BACKGROUND
6
r Slide # 6 CLINICAL BACKGROUND Daniel F. Martin, M.D. Associate Professor of Ophthalmology Emory University School of Medicine u Clinical Features of CMV Retinitis u Impact of HAART u Treatment Options
7
r Slide # 7
8
r Slide # 8
9
r Slide # 9
10
r Slide # 10
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.